SAN CLEMENTE, Calif. (BUSINESS WIRE) Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has enrolled the first patient into a Phase 2 clinical trial o.
Approximately 70% of Subjects were Well-Controlled on iDose TR with the Same or Fewer Topical IOP-Lowering Medications at 36 Months vs. ScreeningFavorable Safety Profile Through 36 MonthsSAN CLEMENTE, Calif. (BUSINESS WIRE) Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical compa.
SAN CLEMENTE, Calif. (BUSINESS WIRE) Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has enrolled the first patient into a Phase 2 clinical trial o.
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced
Glaukos Appoints Denice Torres and Dr Leana Wen to its Board of Directors pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.